Drugs / GSK580416
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00680485 | Jun → Oct 2007 | bacterial infectious disease | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT00427141 | Oct 2006 → ? | bacterial infectious disease, respiratory tract infectious disorder | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK580416 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00680485 ↗ |
| Route | Oral | “GSK580416 oral tablets (250 mg)” NCT00680485 ↗ |